method for assessing whether rheumatoid arthritis exists in vitro through biomarker-associated sample

文档序号：1719074 发布日期：2019-12-17 浏览：27次中文

阅读说明：本技术 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法 (method for assessing whether rheumatoid arthritis exists in vitro through biomarker-associated sample ) 是由饶星廖智星刘宇卉李临其他发明人请求不公开姓名于 2018-07-24 设计创作，主要内容包括：本发明涉及一种用于通过生物化学标记物体外评估类风湿性关节炎(RA)是否存在的方法。该方法通过联合检测血清14-3-3η蛋白、anti-CCP抗体和抗Carp抗体的水平,并将检测结果与RA相关联,可以显著提高RA炎性关节病变患者的RA阳性的检测准确度。(the present invention relates to a method for assessing the presence or absence of Rheumatoid Arthritis (RA) ex vivo by biochemical markers. The method can remarkably improve the detection accuracy of RA positivity of RA inflammatory arthropathy patients by jointly detecting the levels of serum 14-3-3eta protein, anti-CCP antibody and anti-Carp antibody and correlating the detection result with RA.)

1. Use of the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers for the preparation of a reagent for assessing the presence or absence of Rheumatoid Arthritis (RA) ex vivo by biochemical markers comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers in the biomarker group; and

c) Correlating the combined concentration values obtained in step b) with the presence or absence of RA, wherein an increased combined value compared to the truncated combined concentration value of each marker in the respective biomarker panel measured from the reference population is indicative of the presence of RA;

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

2. Use according to claim 1, characterized in that the combined concentration values of step b) are compared with cut-off values derived from a reference population other than RA positive patients, said reference population comprising apparently healthy persons and patients selected from Osteoarthritis (OA) patients and other autoimmune disease patients.

3. use of detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers in the preparation of a reagent for assessing the severity of Rheumatoid Arthritis (RA) by means of biochemical markers in addition, comprising: comprises

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

c) correlating the combined concentration values obtained in step b) with the severity of RA, wherein an increased combined value compared to the truncated combined concentration value of each marker in the respective biomarker panel measured from the reference population is indicative of the severity of RA in the patient;

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

4. Use of the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers for the preparation of a formulation for the classification of Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical labeling of extra-corporeal regions, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

c) distinguishing RA from other autoimmune diseases from the combined concentration values obtained from step b), wherein an increased combined value compared to the truncated combined concentration value of each marker in the corresponding biomarker panel measured from the reference population is indicative for the presence of RA;

wherein the biomarker panel comprises Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies; preferably the other autoimmune diseases include other joint diseases; it is further preferred that the other joint disease is Osteoarthritis (OA).

5. use of a Rheumatoid Arthritis (RA) biomarker panel for the preparation of a reagent for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a test sample, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel as compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population using a heterogeneous chemiluminescent immunoassay is indicative of the presence of RA;

Wherein the biomarkers comprise Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

6. use according to any one of claims 1 to 5, wherein said biomarker panel comprises Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies and other biomarkers, preferably said other biomarker is RA.

7. use according to any one of claims 1 to 6, wherein the concentration of each biomarker in the biomarker panel is detected using a heterogeneous and/or homogeneous chemiluminescent immunoassay.

8. The use according to claim 7, wherein the concentration of Anti-CCP antibodies in the biomarker panel is detected using a heterogeneous chemiluminescence immunoassay, the concentration of 14-3-3eta protein is detected using a heterogeneous chemiluminescence immunoassay, and the Anti-carp antibodies are detected using a heterogeneous or homogeneous chemiluminescence immunoassay.

9. The use according to claim 7, wherein the concentration of Anti-CCP antibodies in the biomarker panel is detected using a heterogeneous chemiluminescence immunoassay, the concentration of 14-3-3eta protein is detected using a homogeneous chemiluminescence immunoassay, and the Anti-carp antibodies are detected using a heterogeneous or homogeneous chemiluminescence immunoassay.

10. Use according to claim 8 or 9, wherein the step of detecting the concentration of Anti-CCP antibodies using heterogeneous chemiluminescence immunoassay comprises measuring the amount of immunocomplexes formed between Anti-CCP antibodies and at least one antigen using heterogeneous chemiluminescence immunoassay.

11. The use according to claim 10, wherein the amount of Anti-CCP antibody in the sample to be tested is determined based on an Anti-CCP standard working curve.

12. the use according to claim 10 or 11, wherein said steps further comprise comparing the amount of immunocomplex formed by said Anti-CCP antibody and at least one antigen measured with the amount of immunocomplex formed by said Anti-CCP antibody and at least one antigen in a normal control sample, a rheumatoid arthritis control sample or a pre-treatment sample from the same subject.

13. use according to any one of claims 10 to 12, wherein said steps comprise contacting said sample with a first antigen comprising an Anti-CCP antibody capable of specifically binding to an epitope binding site of said Anti-CCP antibody to form an immune complex, and further with an Anti-immune complex antibody capable of specifically recognizing and binding to Anti-CCP antibodies in said first immune complex formed with said first antigen, and not recognizing free, antigen-unbound Anti-CCP antibodies.

14. The use according to claim 13, wherein the first antigen is bound directly or indirectly to a solid support and the anti-immunocomplex antibody is bound directly or indirectly to a label capable of reacting with a substrate or capable of catalyzing a detectable signal generated by the substrate.

15. The use according to claim 14 wherein the first antigen is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antigen is bound to biotin and the solid support is bound to streptavidin.

16. the use according to claim 14, wherein the anti-immune complex antibody binds to one member of a specific binding pair member and the label binds to the other member of the specific binding pair member; preferably, the anti-immune complex antibody binds to biotin and the label binds to streptavidin.

17. use according to any one of claims 13 to 16, wherein the first antigen is a citrullinated antigen, preferably the first antigen is selected from the group consisting of synthetic citrullinated cyclic peptides, citrullinated linear peptides, polypeptides formed on one peptide chain by synthesis of at least 2 single citrullinated peptide fragments, a mixture of citrullinated peptide fragments comprising at least 2 single citrullinated peptide fragments, and citrullinated proteins.

18. use according to claim 8 or 9, wherein the step of using a homogeneous chemiluminescent immunoassay for the concentration of 14-3-3eta protein in the biomarker panel comprises measuring the amount of 14-3-3eta protein or fragment thereof or an immune complex formed by said 14-3-3eta protein or fragment thereof and at least one antibody.

19. The use according to claim 18, wherein the content of 14-3-3eta protein in the sample to be tested is determined based on a 14-3-3eta protein standard working curve.

20. The use according to claim 18, wherein said step further comprises comparing the amount of 14-3-3eta protein or fragment thereof or immune complex formed by said 14-3-3eta protein or fragment thereof and at least one antibody measured with the amount of immune complex formed by said 14-3-3eta protein or fragment thereof or said 14-3-3eta protein or fragment thereof and at least one antibody in a normal control sample, a rheumatoid arthritis control sample or a pre-treatment sample from the same subject.

21. Use according to claim 18, characterized in that said step comprises contacting said sample with an antibody comprising an antibody capable of specifically binding to at least one specific epitope of the 14-3-3eta protein or fragment thereof to form an immune complex.

22. The use according to any one of claims 18 to 21, wherein the antibodies comprise a first antibody capable of specifically binding to a first epitope of 14-3-3eta protein and a second antibody capable of specifically binding to a second epitope of 14-3-3eta protein, wherein the second epitope and the first epitope do not overlap.

23. The use according to claim 18, wherein the amino acid SEQUENCE of said 14-3-3eta protein or fragment thereof is as shown in SEQUENCE No. 1.

24. Use according to claim 23, characterized in that said epitope is selected from the relatively specific fragments of the sequence of amino acid fragment 14-3-3eta protein: 1-6aa, 27-38aa, 71-83aa, 112-154 aa and 141-154 aa.

25. a kit of reagents for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises an Anti-CCP antibody, a 14-3-3eta protein and an Anti-carp antibody.

26. A kit of reagents for assessing the severity of Rheumatoid Arthritis (RA) by biochemical marker in vitro based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises an Anti-CCP antibody, a 14-3-3eta protein and an Anti-carp antibody.

27. A kit of reagents for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical marker extracorporal regions based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein, and Anti-carp antibody.

28. A kit of reagents for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a test sample using a Rheumatoid Arthritis (RA) biomarker panel, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel as compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population using a heterogeneous chemiluminescent immunoassay is indicative of the presence of RA; wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

29. the kit of any one of claims 25 to 28, wherein the set of biomarkers comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody and a further biomarker, preferably the further biomarker is RA.

30. The kit of any one of claims 25 to 28, wherein the kit comprises reagents for detecting the concentration of Anti-CCP antibodies, 14-3-3eta protein, and Anti-Carp antibodies in a biomarker panel using heterogeneous chemiluminescence immunoassay.

31. the kit of claim 30, wherein the heterogeneous chemiluminescent immunoassay reagent for detecting Anti-CCP antibodies comprises:

Component a1 comprising a solid support and, directly or indirectly bound thereto, a first antigen capable of specifically binding to an epitope binding site of an anti-CCP antibody;

Component b1 comprising a label capable of reacting with a substrate or capable of catalyzing the substrate to generate a detectable signal and an anti-immune complex antibody directly or indirectly bound thereto, said anti-immune complex antibody being capable of specifically recognizing and binding to anti-CCP antibodies in a first immune complex formed with a first antigen and not recognizing free, antigen-unbound anti-CCP antibodies.

32. The kit of claim 31, wherein the reagent further comprises Anti-CCP antibody pure as a calibrator diluted by a calibrator diluent in a proportional gradient to working calibrator solutions of different concentrations.

33. The kit of any one of claims 31 or 32, wherein the first antigen is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antigen is bound to biotin and the solid support is bound to streptavidin.

34. The kit of any one of claims 31 to 33, wherein the anti-immune complex antibody binds to one member of a specific binding pair member and the label binds to the other member of the specific binding pair member; preferably, the anti-immune complex antibody binds to biotin and the label binds to streptavidin.

35. The reagent set according to claims 31-34, wherein the reagent further comprises component c1, a substrate solution, the substrate solution comprising a1 solution and B1 solution, preferably the a1 solution is a hydrogen peroxide solution, preferably the B1 solution is a sodium hydroxide solution.

36. The kit of claim 35, wherein the heterogeneous chemiluminescent immunoassay reagent for detecting 14-3-3eta protein comprises:

Component a2 comprising a solid support and, directly or indirectly bound thereto, a first antibody or binding fragment thereof capable of specifically binding to a first epitope of 14-3-3eta protein;

component b2 comprising a first label capable of reacting with a substrate or capable of catalysing the substrate to generate a detectable signal and a second antibody or binding fragment thereof directly or indirectly bound to said first label, said second antibody or binding fragment thereof being capable of specifically binding to a second epitope of 14-3-3eta protein, said second epitope and said first epitope not overlapping.

37. The kit of claim 36, wherein the reagent further comprises 14-3-3eta protein as a calibrator diluted by a calibrator diluent in a proportional gradient to working calibrator solutions of different concentrations.

38. The kit of any one of claims 36 or 37, wherein the first antibody or binding fragment thereof is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antibody or binding fragment thereof is bound to biotin and the solid support is bound to streptavidin.

39. a reagent as claimed in any one of claims 36 to 38 wherein the second antibody or binding fragment thereof binds to one member of a specific binding pair member and the first label binds to the other member of the specific binding pair member; preferably, the second antibody or binding fragment thereof is bound to biotin and the first label is bound to streptavidin.

40. The reagent of claims 36 to 39, further comprising a component c2, a substrate solution, wherein the substrate solution comprises an A2 solution and a B2 solution, wherein the A2 solution is preferably a hydrogen peroxide solution, and wherein the B2 solution is preferably a sodium hydroxide solution.

41. The reagent set of any one of claims 36 to 40, wherein the reagent set further comprises a component d2 comprising a second label capable of reacting with a substrate or capable of catalyzing a substrate to generate a detectable signal and a third antibody or binding fragment thereof directly or indirectly bound thereto, wherein the third antibody or binding fragment thereof is capable of specifically binding to a second epitope of the 14-3-3eta protein, and wherein the second epitope and the first epitope do not overlap.

42. The kit of claim 41, wherein the third antibody that directly or indirectly binds to the second label and the second antibody that directly or indirectly binds to the first label are monoclonal antibodies that bind to the same epitope of the 14-3-3eta protein.

43. the kit of claim 41 or 41, wherein the third antibody or binding fragment thereof binds to one member of a specific binding pair member and the second label binds to the other member of the specific binding pair member; preferably, the third antibody or binding fragment thereof binds to biotin and the second label binds to streptavidin.

44. The kit of claim 43, wherein the heterogeneous chemiluminescent immunoassay reagent for the detection of Anti-Carp antibodies comprises:

component a3 comprising a solid support and, directly or indirectly bound thereto, a first antigen capable of specifically binding to an epitope binding site of an Anti-Carp antibody;

Component b3 comprising a label capable of reacting with a substrate or capable of catalyzing the generation of a detectable signal by the substrate and an Anti-immunocomplex antibody directly or indirectly bound thereto, said Anti-immunocomplex antibody being capable of specifically recognizing and binding to an Anti-Carp antibody in a first immunocomplex formed with a first antigen, and not recognizing a free, antigen-unbound Anti-Carp antibody.

45. The kit of claim 44, wherein the reagents further comprise Anti-Carp antibody purified as a calibrator diluted by a calibrator diluent in a proportional gradient to working calibrator solutions of different concentrations.

46. The kit of claim 44 or 45, wherein the first antigen is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antigen is bound to biotin and the solid support is bound to streptavidin.

47. The kit of any one of claims 44 to 46, wherein the anti-immune complex antibody binds to one member of a specific binding pair member and the label binds to the other member of the specific binding pair member; preferably, the anti-immune complex antibody binds to biotin and the label binds to streptavidin.

48. the reagent set of claims 44-47, further comprising component c3, a substrate solution, the substrate solution comprising A3 solution and B3 solution, preferably the A3 solution is hydrogen peroxide solution, preferably the B3 solution is sodium hydroxide solution.

49. A kit for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo based on the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers, comprising the kit of reagents of any one of claims 25-48.

50. A kit for assessing the severity of Rheumatoid Arthritis (RA) by biochemical marker-based on the concentration of each biomarker in a panel of RA biomarkers, comprising the kit of reagents of any one of claims 25-48.

51. A kit for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemically labeling extra-corporeal regions based on the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers, comprising the kit of reagents of any one of claims 25-48.

52. A kit for assessing the presence of Rheumatoid Arthritis (RA) in a test sample in vitro using a Rheumatoid Arthritis (RA) biomarker panel comprising the kit of reagents of any one of claims 25-48.

53. A method for assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using the kit of any one of claims 25-48 or using the kit of claims 49-52 and assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers.

54. the method of claim 53, wherein the method comprises:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers in the biomarker group; and

c) correlating the combined concentration values obtained in step b) with the presence or absence of RA, wherein an increased combined value compared to the truncated combined concentration value of each marker in the respective biomarker panel measured from the reference population is indicative of the presence of RA;

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

55. The method of claim 54, wherein the combined concentration values of step b) are compared to cut-off values derived from a reference population other than RA-positive patients, the reference population comprising apparently healthy persons and patients selected from Osteoarthritis (OA) patients and other autoimmune disease patients.

56. A method for assessing the severity of Rheumatoid Arthritis (RA) by the external biochemical marker, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using the kit of any one of claims 25-48 or using the kit of claims 49-52 and assessing the severity of Rheumatoid Arthritis (RA) by the external biochemical marker.

57. the method of claim 56, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

c) Correlating the combined concentration values obtained in step b) with the severity of RA, wherein an increased combined value compared to the truncated combined concentration value of each marker in the respective biomarker panel measured from the reference population is indicative of the severity of RA in the patient;

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

58. a method of classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical labeling of extra-corporeal regions, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using the kit of any one of claims 25 to 48 or using the kit of claims 49 to 52 and classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical labeling of extra-corporeal regions.

59. The method of claim 58, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

c) Distinguishing RA from other autoimmune diseases from the combined concentration values obtained from step b), wherein an increased combined value compared to the truncated combined concentration value of each marker in the corresponding biomarker panel measured from the reference population is indicative for the presence of RA;

Wherein the biomarker panel comprises Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies; preferably the other autoimmune diseases include other joint diseases; preferably the other joint disease is Osteoarthritis (OA).

60. a method for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a test sample using the kit of any one of claims 25-48 or using the kit of claims 49-52, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel as compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population is indicative of the presence of RA;

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

61. the method according to any one of claims 53 to 60, wherein said set of biomarkers comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody and a further biomarker, preferably said further biomarker is RF.

62. the method of claims 53 to 61, wherein the kit of reagents of any one of claims 31 to 35 is used to detect the concentration of Anti-CCP antibodies by heterogeneous chemiluminescence immunoassay comprising:

step R1, mixing a sample to be tested with the component a1 to obtain a first mixture;

Step R2, mixing the first mixture with component b1 to obtain a second mixture;

step R3, mixing the second mixture with component c1 to obtain a third mixture which generates a detectable chemiluminescent signal;

and step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of Anti-CCP antibody.

63. The method of claim 62 further comprising the step of creating a standard working curve for Anti-CCP antibody prior to step R1.

64. the method of claim 63, wherein in step R4, the intensity of said chemiluminescent signal of step R3 is detected, and the amount of Anti-CCP antibody in the sample is determined based on the Anti-CCP standard working curve.

65. The method according to claims 53 to 61, wherein the kit of reagents according to any one of claims 36 to 43 is used to detect the concentration of 14-3-3eta protein by heterogeneous chemiluminescence immunoassay, comprising:

Step R1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

step R2, mixing the third mixture with component c2 to obtain a fourth mixture which generates a detectable signal;

Step R3, detecting the existence and/or the intensity of the chemiluminescence signal in the step R2, so as to judge whether the 14-3-3eta protein exists in the sample to be detected and/or determine the content of the 14-3-3eta protein;

Or comprises the following steps:

step T1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step T2, mixing the third mixture with component d2 to obtain a fifth mixture;

A step T3 of mixing the fifth mixture with component c2 to obtain a sixth mixture generating a detectable signal;

And detecting the existence and/or the intensity of the chemiluminescence signal in the step T3, thereby judging whether the 14-3-3eta protein exists in the sample to be detected and/or determining the content of the 14-3-3eta protein.

66. the method of claim 65, further comprising the step of preparing a standard working curve for 14-3-3eta protein prior to step R1 or T1.

67. the method of claim 66, wherein in step R3 or T3, the intensity of the chemiluminescent signal of step R2 or T2 is measured and the content of 14-3-3eta protein in the test sample is determined based on a 14-3-3eta protein standard working curve.

68. The method according to claims 53 to 61, wherein the kit of reagents according to any one of claims 44 to 48 is used to detect the concentration of Anti-Carp antibody by heterogeneous chemiluminescence immunoassay comprising:

step R1, mixing a sample to be tested with the component a3 to obtain a first mixture;

Step R2, mixing the first mixture with component b3 to obtain a second mixture;

Step R3, mixing the second mixture with component c3 to obtain a third mixture which generates a detectable chemiluminescent signal;

and step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of the Anti-Carp antibody.

69. The method according to claim 68, further comprising a step of preparing an Anti-Carp antibody standard working curve before step R1.

70. The method of claim 69, wherein in step R4, the intensity of the chemiluminescent signal of step R3 is detected, and the amount of Anti-Carp antibody in the test sample is determined based on an Anti-Carp antibody standard working curve.

71. use of the heterogeneous chemiluminescent immunoassay kit of any one of claims 25 to 48 or the heterogeneous chemiluminescent immunoassay kit of any one of claims 49 to 52 or the heterogeneous chemiluminescent immunoassay method of any one of claims 53 to 70 in a chemiluminescent immunoassay analyzer.

72. The chemiluminescent immunoassay analyzer of claim 71 in use comprising:

a sample filling module for filling a sample to be tested of a subject suspected of having rheumatoid arthritis to a preset position of a chemiluminescence analyzer;

the reagent filling module is used for filling the pipettes of various reagents to the preset position of the chemiluminescence analyzer;

the incubation module is used for providing a proper incubation reaction environment for immunoreaction of a sample to be detected and a reagent;

The magnetic separation module is used for cleaning the magnetic particles in the reaction mixed liquid, discharging the reaction liquid after incubation reaction and leaving the cleaned magnetic particles;

A detection module for detecting the chemiluminescence signal and determining the concentration of the target molecule in the sample to be detected

and the electric control module is used for coordinating and controlling the incubation module, the sample filling module, the reagent filling module, the magnetic separation module and the detection module to act according to a set program.

Technical Field

The invention belongs to the technical field of immunoassay, and particularly relates to a kit for evaluating whether rheumatoid arthritis exists in vitro through a biomarker-associated sample, a preparation method and a use method.

Background

Biomarkers (biomarkers) are biochemical markers that can mark changes or changes that may occur in the structure or function of systems, organs, tissues, cells, and subcellular structures and functions, and have a wide range of uses.

rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized primarily by synovitis, with clinical manifestations dominated by chronic polyarthritis, which ultimately leads to joint deformity. The biomarker is used for comprehensively judging the disease course, the illness state, the genetic background, the epigenetics and other characteristics of the RA patient, so that the accurate diagnosis and treatment of RA can be realized, and the survival quality of the RA patient is improved. Therefore, how to improve the detection accuracy of RA positivity of RA inflammatory arthropathy patients is an urgent technical problem to be solved.

disclosure of Invention

To solve the above technical problems, the present invention provides a method for assessing the presence or absence of rheumatoid arthritis in vitro by biomarker-linked samples. The method can remarkably improve the detection accuracy of RA positivity of RA inflammatory arthropathy patients by jointly detecting the levels of serum 14-3-3eta protein, anti-CCP antibody and anti-Carp antibody and correlating the detection result with RA.

To this end, the present invention provides, in a first aspect, the use of the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers for the preparation of an agent for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers in the biomarker group; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in some embodiments of the invention, the combined concentration values of step b) are compared to cut-off values derived from a reference population other than RA positive patients, said reference population comprising apparently healthy patients and patients selected from Osteoarthritis (OA) patients and other autoimmune disease patients.

In a second aspect, the present invention provides a use of detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel in the preparation of a reagent for assessing the severity of Rheumatoid Arthritis (RA) by biochemical markers, comprising:

a) respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In a third aspect, the present invention provides a use of the concentration of each biomarker in a panel of biomarkers for Rheumatoid Arthritis (RA) for the preparation of a formulation for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical labeling of extra-corporeal regions, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in some embodiments of the invention, the other autoimmune diseases include other joint diseases; the other joint disease is Osteoarthritis (OA).

in a fourth aspect, the invention provides the use of a Rheumatoid Arthritis (RA) biomarker panel for the preparation of a reagent for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a sample to be tested, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel using a heterogeneous chemiluminescent immunoassay compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population is indicative of the presence of RA;

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In the present invention, the sample to be tested is selected from blood, blood derivatives, serum, plasma, urine, cerebrospinal fluid, semen, saliva, synovial fluid, emphysema effusion and tissue.

According to the use of the first to fourth aspects of the invention, the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody and a further biomarker, preferably the further biomarker is RA.

In some preferred embodiments of the invention, the concentration of each biomarker in the biomarker panel is detected using a heterogeneous chemiluminescence immunoassay.

In some embodiments of the invention, the concentration of Anti-CCP antibodies in the biomarker panel is detected using a heterogeneous chemiluminescence immunoassay, the concentration of 14-3-3eta protein is detected using a heterogeneous chemiluminescence immunoassay, and the Anti-carp antibodies are detected using a heterogeneous or homogeneous chemiluminescence immunoassay.

In other embodiments of the invention, the concentration of Anti-CCP antibodies in the biomarker panel is detected using a heterogeneous chemiluminescence immunoassay, the concentration of 14-3-3eta protein is detected using a homogeneous chemiluminescence immunoassay, and the Anti-carp antibodies are detected using a heterogeneous or homogeneous chemiluminescence immunoassay.

According to some embodiments of the invention, the step of detecting the concentration of Anti-CCP antibodies using a heterogeneous chemiluminescence immunoassay comprises measuring the amount of immunocomplexes formed between Anti-CCP antibodies and at least one antigen using a heterogeneous chemiluminescence immunoassay.

In some embodiments of the invention, the amount of Anti-CCP antibody in the sample to be tested is determined based on an Anti-CCP standard working curve.

According to some embodiments of the invention, said step further comprises comparing the amount of immunocomplexes formed between said Anti-CCP antibody and at least one antigen measured with the amount of immunocomplexes formed between said Anti-CCP antibody and at least one antigen in a normal control sample, a rheumatoid arthritis control sample or a pre-treatment sample from the same subject.

according to some embodiments of the invention, the step comprises contacting the sample with a sample comprising a first antigen capable of specifically binding to the epitope binding site of Anti-CCP antibodies to form an immune complex, and further with an Anti-immune complex antibody capable of specifically recognizing and binding to Anti-CCP antibodies in the first immune complex formed with the first antigen, and not recognizing free, antigen-unbound Anti-CCP antibodies.

In the present invention, the first antigen is bound directly or indirectly to a solid support, and the anti-immunocomplex antibody is bound directly or indirectly to a label capable of reacting with a substrate or capable of catalyzing a detectable signal generated by the substrate.

in some embodiments of the invention, the first antigen is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antigen is bound to biotin and the solid support is bound to streptavidin.

in some embodiments of the invention, the anti-immune complex antibody binds to one member of a specific binding pair member and the label binds to the other member of the specific binding pair member; preferably, the anti-immune complex antibody binds to biotin and the label binds to streptavidin.

In some embodiments of the invention, the first antigen is a citrullinated antigen.

In some preferred embodiments of the invention, the first antigen is selected from the group consisting of synthetic citrullinated cyclic peptides, citrullinated linear peptides, polypeptides formed by synthesizing at least 2 single citrullinated peptide fragments on one peptide chain, a mixture of citrullinated peptide fragments comprising at least 2 single citrullinated peptide fragments, and citrullinated proteins

according to some embodiments of the invention, the step of using a homogeneous chemiluminescent immunoassay for the concentration of 14-3-3eta protein in the biomarker panel comprises measuring the amount of 14-3-3eta protein or fragment thereof or an immune complex formed by said 14-3-3eta protein or fragment thereof and at least one antibody.

in some embodiments of the invention, the amount of 14-3-3eta protein in the test sample is determined based on a 14-3-3eta protein standard working curve.

According to some embodiments of the invention, said step further comprises comparing the measured amount of 14-3-3eta protein or fragment thereof or immune complex formed by said 14-3-3eta protein or fragment thereof and at least one antibody with the amount of immune complex formed by said 14-3-3eta protein or fragment thereof or said 14-3-3eta protein or fragment thereof and at least one antibody in a normal control sample, a rheumatoid arthritis control sample or a pre-treatment sample from the same subject.

according to some embodiments of the invention, the step comprises specifically binding the sample to an antibody comprising an epitope capable of forming an immune complex with at least one specific epitope of the 14-3-3eta protein or fragment thereof.

In some embodiments of the invention, the antibody comprises a first antibody capable of specifically binding to a first epitope of 14-3-3eta protein and a second antibody capable of specifically binding to a second epitope of 14-3-3eta protein, wherein the second epitope and the first epitope do not overlap.

In the present invention, the first antibody binds to a receptor capable of reacting with singlet oxygen to generate a detectable chemiluminescent signal.

in some embodiments of the invention, the acceptor comprises an olefinic compound and a metal chelate, which is in non-particulate form and soluble in an aqueous medium; and/or the acceptor is polymer particles filled with a luminescent compound and lanthanide.

In the present invention, the first antibody and the second antibody are each independently selected from a monoclonal antibody and/or a polyclonal antibody, preferably a monoclonal antibody.

In some embodiments of the invention, the amino acid SEQUENCE of the 14-3-3eta protein or fragment thereof is as shown in SEQUENCE No. 1.

In some further embodiments of the invention, the epitope is selected from the group consisting of relatively specific fragments whose amino acid fragments are sequences of 14-3-3eta protein: 1-6aa, 27-38aa, 71-83aa, 112-154 aa and 141-154 aa.

In a fifth aspect, the present invention provides a kit of reagents for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in the Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises Anti-CCP antibodies, 14-3-3eta protein, and Anti-carp antibodies.

The sixth aspect of the present invention provides a kit for assessing the severity of Rheumatoid Arthritis (RA) by biochemical marker in vitro based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in the Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein, and Anti-carp antibody.

The seventh aspect of the present invention provides a kit of reagents for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical marker extracellular region based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein, and Anti-carp antibody.

an eighth aspect of the invention provides a kit of reagents for the in vitro assessment of the presence or absence of Rheumatoid Arthritis (RA) in a sample to be tested using a Rheumatoid Arthritis (RA) biomarker panel, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel using a heterogeneous chemiluminescent immunoassay compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population is indicative of the presence of RA; wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

According to the kit of parts according to the fifth to eighth aspect of the invention, the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody and other biomarkers, preferably the other biomarkers are RA.

In the present invention, the sample to be tested is selected from blood, blood derivatives, serum, plasma, urine, cerebrospinal fluid, semen, saliva, synovial fluid, emphysema effusion and tissue.

The kit according to the fifth to eighth aspects of the present invention, which comprises reagents for detecting the concentrations of Anti-CCP antibody, 14-3-3eta protein and Anti-Carp antibody in the biomarker panel by heterogeneous chemiluminescence immunoassay.

According to some embodiments of the invention, the heterogeneous chemiluminescent immunoassay reagent for the detection of Anti-CCP antibodies comprises:

Component a1 comprising a solid support and, directly or indirectly bound thereto, a first antigen capable of specifically binding to an epitope binding site of an anti-CCP antibody;

in some embodiments of the present invention, the reagent further comprises Anti-CCP pure product as a calibrator, and the calibrator is diluted by calibrator diluent to working calibrator solutions with different concentrations according to a proportional gradient.

In some embodiments of the invention, the first antigen is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antigen is bound to biotin and the solid support is bound to streptavidin.

In some embodiments of the invention, the anti-immune complex antibody binds to one member of a specific binding pair member and the label binds to the other member of the specific binding pair member; preferably, the anti-immune complex antibody binds to biotin and the label binds to streptavidin.

In some embodiments of the invention, the reagent further comprises component c1, a substrate solution, the substrate solution comprising a1 solution and a B1 solution, preferably the a1 solution is a hydrogen peroxide solution, and preferably the B1 solution is a sodium hydroxide solution.

according to some embodiments of the invention, the heterogeneous chemiluminescent immunoassay reagent for the detection of 14-3-3eta protein comprises:

In some embodiments of the invention, the reagent further comprises 14-3-3eta protein pure product as a calibrator, and the calibrator is diluted by calibrator diluent according to a proportional gradient to working calibrator solutions with different concentrations.

In some embodiments of the invention, the first antibody or binding fragment thereof is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antibody or binding fragment thereof is bound to biotin and the solid support is bound to streptavidin.

In some embodiments of the invention, the second antibody or binding fragment thereof binds to one member of a specific binding pair member and the first label binds to the other member of the specific binding pair member; preferably, the second antibody or binding fragment thereof is bound to biotin and the first label is bound to streptavidin.

In some embodiments of the invention, the reagent further comprises component c2, a substrate solution, the substrate solution comprising a2 solution and a B2 solution, preferably the a2 solution is a hydrogen peroxide solution, and preferably the B2 solution is a sodium hydroxide solution.

In some embodiments of the invention, the reagent further comprises a component d2 comprising a second label capable of reacting with the substrate or capable of catalyzing the substrate to generate a detectable signal, and a third antibody or binding fragment thereof directly or indirectly bound thereto, the third antibody or binding fragment thereof being capable of specifically binding to a second epitope of the 14-3-3eta protein, and the second epitope and the first epitope are non-overlapping.

In some preferred embodiments of the invention, the third antibody that directly or indirectly binds to the second label and the second antibody that directly or indirectly binds to the first label are monoclonal antibodies that bind to the same epitope of the 14-3-3eta protein.

in some embodiments of the invention, the third antibody or binding fragment thereof binds to one member of the specific binding pair member and the second label binds to the other member of the specific binding pair member; preferably, the third antibody or binding fragment thereof binds to biotin and the second label binds to streptavidin.

According to some embodiments of the invention, the heterogeneous chemiluminescent immunoassay reagent for the detection of Anti-Carp antibodies comprises:

Component a3 comprising a solid support and, directly or indirectly bound thereto, a first antigen capable of specifically binding to an epitope binding site of an Anti-Carp antibody;

component b3 comprising a label capable of reacting with a substrate or capable of catalyzing the generation of a detectable signal by the substrate and an Anti-immunocomplex antibody directly or indirectly bound thereto, said Anti-immunocomplex antibody being capable of specifically recognizing and binding to an Anti-Carp antibody in a first immunocomplex formed with a first antigen, and not recognizing a free, antigen-unbound Anti-Carp antibody.

In some embodiments of the invention, the reagent further comprises Anti-Carp antibody pure product as a calibrator, and the calibrator is diluted by calibrator diluent according to a proportional gradient to working calibrator solutions with different concentrations.

In some embodiments of the invention, component c3, a substrate solution, said substrate solution comprising A3 solution and a B3 solution, preferably said A3 solution is a hydrogen peroxide solution, preferably said B3 solution is a sodium hydroxide solution.

in a ninth aspect, the invention provides a kit for assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers based on the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers, comprising a kit of reagents according to the fifth to eighth aspects of the invention.

in a tenth aspect, the invention provides a kit for assessing the severity of Rheumatoid Arthritis (RA) by means of biochemical markers in addition to the biomarkers based on the concentration of each biomarker in a set of Rheumatoid Arthritis (RA) biomarkers, comprising a kit of reagents according to the fifth to eighth aspects of the invention.

The eleventh aspect of the present invention provides a kit for classifying Rheumatoid Arthritis (RA) and other autoimmune diseases by biochemically labeling extra-corporeal regions based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising the kit of reagents according to the fifth to eighth aspects of the present invention.

In a twelfth aspect, the invention provides a kit for assessing the presence of Rheumatoid Arthritis (RA) in a test sample in vitro using a Rheumatoid Arthritis (RA) biomarker panel, comprising the kit of parts according to the fifth to eighth aspects of the invention.

In a thirteenth aspect, the present invention provides a method for assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using a kit of reagents according to the fifth to eighth aspects of the present invention or using a kit according to the ninth to twelfth aspects of the present invention and assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers.

In some embodiments of the invention, the method comprises:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers in the biomarker group; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In some embodiments of the invention, the combined concentration values of step b) are compared to cut-off values derived from a reference population other than RA positive patients, said reference population comprising apparently healthy patients and patients selected from Osteoarthritis (OA) patients and other autoimmune disease patients.

In a fourteenth aspect, the present invention provides a method for assessing the severity of Rheumatoid Arthritis (RA) by the presence of biochemical markers, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using a kit of reagents according to the fifth to eighth aspects of the invention or using a kit according to the ninth to twelfth aspects of the invention and assessing the severity of Rheumatoid Arthritis (RA) by the presence of biochemical markers.

in some embodiments of the invention, the method comprises:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in a fifteenth aspect, the present invention provides a method for classifying Rheumatoid Arthritis (RA) and other autoimmune diseases by biochemical labeling of extracellular regions, comprising detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel using a kit of reagents as described in the fifth to eighth aspects of the present invention or using a kit as described in the ninth to twelfth aspects of the present invention and classifying Rheumatoid Arthritis (RA) and other autoimmune diseases by biochemical labeling of extracellular regions.

In some embodiments of the invention, the method comprises:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In some embodiments of the invention, the other autoimmune diseases include other joint diseases; the other joint disease is Osteoarthritis (OA).

a sixteenth aspect of the invention provides a method for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a test sample using a kit of reagents according to the fifth to eighth aspects of the invention or using a kit according to the ninth to twelfth aspects of the invention, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel compared to the truncated combined concentration value measured for each marker in the corresponding biomarker panel from a reference population is indicative of the presence of RA;

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in the present invention, the sample to be tested is selected from blood, blood derivatives, serum, plasma, urine, cerebrospinal fluid, semen, saliva, synovial fluid, emphysema effusion and tissue.

In some embodiments of the invention, the set of biomarkers comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody and other biomarkers, preferably RF.

According to the method of the thirteenth to sixteenth aspects of the present invention, the concentration of Anti-CCP antibody is measured by a heterogeneous chemiluminescence immunoassay using a heterogeneous chemiluminescence immunoassay kit containing Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody, comprising:

step R1, mixing a sample to be tested with the component a1 to obtain a first mixture;

Step R2, mixing the first mixture with component b1 to obtain a second mixture;

Step R3, mixing the second mixture with component c1 to obtain a third mixture which generates a detectable chemiluminescent signal;

And step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of Anti-CCP antibody.

In some embodiments of the invention, the method further comprises the step of preparing an Anti-CCP standard working curve before step R1.

In some embodiments of the present invention, in step R4, the intensity of the chemiluminescence signal in step R3 is detected, and the content of Anti-CCP antibody in the sample to be tested is determined based on the Anti-CCP antibody standard working curve.

According to the method of the thirteenth to sixteenth aspects of the present invention, the concentration of 14-3-3eta protein is detected by heterogeneous chemiluminescence immunoassay using a heterogeneous chemiluminescence immunoassay kit containing Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody, comprising:

step R1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step R2, mixing the third mixture with component c2 to obtain a fourth mixture which generates a detectable signal;

Or comprises the following steps:

step T1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step T2, mixing the third mixture with component d2 to obtain a fifth mixture;

a step T3 of mixing the fifth mixture with component c2 to obtain a sixth mixture generating a detectable signal;

In some embodiments of the invention, the method further comprises the step of preparing a standard working curve for the 14-3-3eta protein prior to step R1 or T1.

in some embodiments of the present invention, in the step R3 or T3, the intensity of the chemiluminescent signal in the step R2 or T2 is detected, and the content of the 14-3-3eta protein in the sample to be tested is determined based on the 14-3-3eta protein standard working curve.

According to the method of the thirteenth to sixteenth aspects of the present invention, the concentration of Anti-Carp antibody is detected by heterogeneous chemiluminescence immunoassay using a heterogeneous chemiluminescence immunoassay kit comprising Anti-CCP antibody, 14-3-3eta protein and Anti-Carp antibody, comprising:

step R1, mixing a sample to be tested with the component a3 to obtain a first mixture;

Step R2, mixing the first mixture with component b3 to obtain a second mixture;

step R3, mixing the second mixture with component c3 to obtain a third mixture which generates a detectable chemiluminescent signal;

and step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of the Anti-Carp antibody.

In some embodiments of the invention, the method further comprises the step of creating an Anti-Carp antibody standard working curve prior to step R1.

in some embodiments of the present invention, in step R4, the intensity of the chemiluminescent signal described in step R3 is detected, and the content of Anti-Carp antibody in the sample to be tested is determined based on the Anti-Carp antibody standard working curve.

a seventeenth aspect of the invention provides a kit of reagents according to the fifth to eighth aspects of the invention or the use of a kit according to the ninth to twelfth aspects of the invention or a heterogeneous chemiluminescent immunoassay according to the thirteenth to sixteenth aspects of the invention in a chemiluminescent immunoassay analyzer.

An eighteenth aspect of the invention provides the chemiluminescent immunoassay analyzer of the use of the seventeenth aspect comprising:

A sample filling module for filling a sample to be tested of a subject suspected of having rheumatoid arthritis to a preset position of a chemiluminescence analyzer;

The reagent filling module is used for filling the pipettes of various reagents to the preset position of the chemiluminescence analyzer;

The incubation module is used for providing a proper incubation reaction environment for immunoreaction of a sample to be detected and a reagent;

A detection module for detecting the chemiluminescence signal and determining the concentration of the target molecule in the sample to be detected

And the electric control module is used for coordinating and controlling the incubation module, the sample filling module, the reagent filling module, the magnetic separation module and the detection module to act according to a set program.

In a nineteenth aspect of the present invention, there is provided a homogeneous immunoassay method for detecting Anti-CCP, using the chemiluminescent immunoassay system according to the eighteenth aspect of the present invention, and a heterogeneous immunoassay kit or kit containing a reagent for detecting Anti-CCP, 14-3-3eta protein and Anti-carp antibody according to the present invention, for detecting the concentration of Anti-CCP by homogeneous immunoassay, comprising:

Step R1, mixing a sample to be tested with the component a1 to obtain a first mixture;

Step R2, mixing the first mixture with component b1 to obtain a second mixture;

Step R3, mixing the second mixture with component c1 to obtain a third mixture which generates a detectable chemiluminescent signal;

And step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of Anti-CCP antibody.

in some embodiments of the invention, the method further comprises the step of preparing an Anti-CCP standard working curve before step R1.

in some embodiments of the present invention, in step R4, the intensity of the chemiluminescence signal in step R3 is detected, and the content of Anti-CCP antibody in the sample to be tested is determined based on the Anti-CCP antibody standard working curve.

In a twentieth aspect, the present invention provides a homogeneous immunoassay method for detecting 14-3-3eta protein, which employs the chemiluminescent immunoassay system of the eighteenth aspect of the present invention, and a heterogeneous immunoassay kit or kit containing antibodies for detecting Anti-CCP, 14-3-3eta protein and Anti-carp, as described in the present invention, to detect the concentration of 14-3-3eta protein by homogeneous immunoassay, comprising:

Step R1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step R2, mixing the third mixture with component c2 to obtain a fourth mixture which generates a detectable signal;

Or comprises the following steps:

step T1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step T2, mixing the third mixture with component d2 to obtain a fifth mixture;

a step T3 of mixing the fifth mixture with component c2 to obtain a sixth mixture generating a detectable signal;

In some embodiments of the invention, the method further comprises the step of preparing a standard working curve for the 14-3-3eta protein prior to step R1 or T1.

In some embodiments of the present invention, in the step R3 or T3, the intensity of the chemiluminescent signal in the step R2 or T2 is detected, and the content of the 14-3-3eta protein in the sample to be tested is determined based on the 14-3-3eta protein standard working curve.

According to a twenty-first aspect of the present invention, there is provided a homogeneous immunoassay method for detecting an Anti-Carp antibody using the chemiluminescent immunoassay system according to the eighteenth aspect of the present invention and a homogeneous immunoassay kit or kit comprising a homogeneous immunoassay reagent set for detecting Anti-CCP antibody, 14-3-3eta protein and Anti-Carp antibody according to the present invention for detecting the concentration of the Anti-Carp antibody by homogeneous immunoassay, comprising:

Step R1, mixing a sample to be tested with the component a3 to obtain a first mixture;

Step R2, mixing the first mixture with component b3 to obtain a second mixture;

Step R3, mixing the second mixture with component c3 to obtain a third mixture which generates a detectable chemiluminescent signal;

and step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of the Anti-Carp antibody.

in some embodiments of the invention, the method further comprises the step of creating an Anti-Carp antibody standard working curve prior to step R1.

In some embodiments of the present invention, in step R4, the intensity of the chemiluminescent signal described in step R3 is detected, and the content of Anti-Carp antibody in the sample to be tested is determined based on the Anti-Carp antibody standard working curve.

the method for assessing whether the Rheumatoid Arthritis (RA) exists in vitro through the biochemical markers provided by the invention can obviously improve the detection accuracy of RA positivity of RA inflammatory arthropathy patients by jointly detecting the levels of serum 14-3-3eta protein, anti-CCP antibody and anti-Carp antibody and correlating the detection result with RA.

Detailed Description

in order that the invention may be readily understood, a detailed description of the invention is provided below. However, before the invention is described in detail, it is to be understood that this invention is not limited to particular embodiments described. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

where a range of values is provided, it is understood that each intervening value, to the extent that there is no stated or intervening value in that stated range, to the extent that there is no such intervening value, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where a specified range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

Unless otherwise defined, all terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described.

Term (I)

"subject", "subject" and "patient" are used interchangeably and, without particular reference or limitation, refer to mammals such as humans and non-human primates, as well as rabbits, rats, mice, goats, pigs and other mammalian species.

The term "homogeneous" as used herein is defined in english as "homogeneous" and means that the bound antigen-antibody complex and the remaining free antigen or antibody are detected without separation.

The term "heterogeneous" is used herein in the english language to define "heterology" and means that the bound antigen-antibody complex and the remaining free antigen or antibody are separated for detection.

the term "test sample" as used herein refers to a mixture that may contain an analyte, including but not limited to a protein, hormone, antibody or antigen. Typical test samples that can be used in the disclosed methods include body fluids and tissues such as blood, blood derivatives, serum, plasma, urine, cerebrospinal fluid, semen, saliva, synovial fluid, emphysema fluid and tissues, and the like.

the term "citrullinated peptide" as used herein refers to a specific antigen that reacts positively with RA serum: the modified polypeptide fragments include serine fragment, pre-serine precursor, synthesized polypeptide, recombinant polypeptide, marker-coupled polypeptide and other modified polypeptide fragments, and features that the modified polypeptide fragments contain citrulline, which is essential component for the recognition of CCP antibody.

The term "citrulline epitope" as used herein refers to a region on the surface of an antigen to which an anti-cyclic citrullinated peptide antibody can specifically bind, including citrulline residues and surrounding amino acid sequences in which the citrulline residues are located.

The term "epitope recognition site of an anti-cyclic citrullinated peptide antibody" also referred to as "epitope recognition site" as used herein means a region of the anti-cyclic citrullinated peptide antibody that recognizes and binds to a "citrullinated epitope", for example, a first recognition site of an epitope of an anti-cyclic citrullinated peptide antibody and a second recognition site of an epitope of an anti-cyclic citrullinated peptide antibody do not overlap, i.e., belong to different epitope recognition sites with the same binding property.

The term "citrulline peptide fragment mixture" as used herein refers to a mixture formed by mixing at least 2 single citrulline-containing peptide fragments, wherein the citrulline-containing peptide fragments can be cyclic peptide fragments containing citrulline or linear peptide fragments containing citrulline.

The terms "14-3-3" and "14-3-3 protein" are used interchangeably herein and refer to at least one member of the 14-3-3 family of conserved intracellular regulatory molecules that are ubiquitously expressed in eukaryotic cells. The 14-3-3 protein has the ability to bind a number of functionally diverse signal transduction proteins, including kinases, phosphatases and transmembrane receptors. Indeed, more than 100 signal transduction proteins have been reported as ligands for 14-3-3. The 14-3-3 protein can be considered as an evolved member of the tetrico peptide repeat superfamily. They typically have 9 or 10 alpha helices, often forming homodimer and/or heterodimer interactions along their amino terminal helices. These proteins contain a number of known domains including regions for divalent cation interactions, phosphorylation & acetylation, and proteolytic cleavage, among others. Seven different genetically encoded 14-3-3 protein isoforms, each comprising 242-255 amino acids, are known to be expressed in mammals. The seven 14-3-3 protein isoforms are designated 14-3-3 α/β (alpha/beta), 14-3-3 δ/ξ (delta/zeta), 14-3-3 ε (epsilon), 14-3-3 γ (gamma), 14-3-3 η (eta), 14-3-3 η/θ (tau/theta) and 14-3-3 ζ (sigma/stratfin). The 14-3-3 protein has a high degree of sequence similarity and is known to undergo post-translational processing such as phosphorylation, citrullination, and the like. See, e.g., Megidish et al (1998) J.biol.chem.273: 21834-45. Thus, an anti-14-3-3 autoantibody may specifically bind to and/or recognize more than one 14-3-3 protein isoform, or may specifically bind to and/or recognize only one isoform (e.g., 14-3-3 η). In addition, anti-14-3-3 antibodies can bind to and/or recognize 14-3-3-protein that has been modified, e.g., naturally (e.g., post-translationally) or chemically.

the term "relatively specific fragment" as used herein means that, with respect to 7 isoforms of 14-3-3 protein of the 14-3-3 family, the present inventors found through studies that fragments 1-6aa, 27-38aa, 71-83aa, 112-154 aa and 141-154aa in the amino acid SEQUENCE of 14-3-3eta protein or a fragment thereof as represented by SEQ ID NO.1 are specific epitopes belonging only to the 14-3-3eta (eta) protein, it does not have any cross-over with the amino acid sequence of the other 6 isoforms of the 14-3-3 family 14-3-3 protein, and the monoclonal antibody produced therefrom recognizes or binds only the 14-3-3eta (eta) protein and does not recognize or bind to the other 6 isoforms of the 14-3-3 family 14-3-3 protein.

in the present invention, the term "arthritis" is used interchangeably with "arthritic conditions" and "joint pain", and generally refers to inflammatory conditions of human joints, unless otherwise indicated. Pain, swelling, stiffness and difficulty moving are often associated with arthritic conditions. Arthritis consists of more than 100 different cases. These conditions can be anything from a relatively mild form to a severely compromised system form. Arthritic conditions can be caused by any of a variety of causes, including infection, trauma, degenerative disease, metabolic disorder or disturbance, or other unknown etiology. Arthritic conditions can be more particularly described in terms of subtypes such as rheumatoid arthritis, Mixed Connective Tissue Disease (MCTD), crystal arthritis, reactive arthritis, spondyloarthropathies, osteoarthritis, sarcoidosis, recurrent rheumatism, post-traumatic arthritis, malignancy-associated arthritis, septic arthritis, lyme arthritis, osteoarthritis, bacterial infectious arthritis, and the like. Arthritis may also be accompanied by other identified diseases including gout, ankylosing spondylitis, systemic lupus erythematosus, inflammatory bowel disease, psoriasis, and the like. A well-defined arthritic condition refers to the knowledge about the type of arthritis and its stage, e.g., onset, remission, relapse, and the like.

The terms "antibody" and "immunoglobulin" are used in the broadest sense of the invention, and include antibodies or immunoglobulins of any isotype, antibody fragments that retain specific binding to an antigen; including but not limited to Fab, Fv, scFv, Fd fragments, chimeric antibodies, humanized antibodies, single chain antibodies, bispecific antibodies, and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. In any case desired, the antibody may be further conjugated to other moieties, such as a specific binding pair member, e.g., biotin or streptavidin (a member of a biotin-streptavidin specific binding pair member), and the like.

The term "immune complex" (antigen-antibody complex) as used herein; the "human immune complex" refers to an immune complex existing in a human body, and may be an immune complex existing in blood circulation or an immune complex deposited in a tissue.

the term "anti-immunocomplex antibody" as used herein refers to a substance that specifically recognizes and binds to an antigen-antibody immunocomplex, and does not recognize free, antigen-unbound antibodies and free human IgG antibodies. Specifically, the specific antibody in the sample is combined with the corresponding antigen to form an antigen-antibody-immune complex, and the conformation or epitope of the antibody in the immune complex state is changed and shows a difference from the conformation or epitope of other free non-specific antibodies, and the difference is specifically recognized by the anti-immune complex antibody provided by the invention. The use of such anti-immune complex antibodies allows discrimination between antibodies in the immune complex state and non-specific antibodies, free specific antibodies not bound to the antigen.

The term "monoclonal antibody" as used herein refers to an immunoglobulin secreted from a monoclonal B lymphocyte, which can be prepared by methods known to those skilled in the art.

the term "polyclonal antibody" as used herein refers to a collection of immunoglobulins produced by more than one B lymphocyte clone, which may be prepared by methods well known to those skilled in the art.

The term "antigen" as used herein refers to a substance that stimulates the body to produce an immune response and that binds to the immune response product antibodies and sensitized lymphocytes in vitro and in vivo to produce an immune effect.

The term "binding" as used herein refers to direct association between two molecules due to interactions such as covalent, electrostatic, hydrophobic, ionic and/or hydrogen bonding, including but not limited to interactions such as salt and water bridges.

The term "specific binding" or "specific binding" as used herein refers to the mutual discrimination and selective binding reaction between two substances, and is the conformational correspondence between the corresponding reactants from the perspective of the three-dimensional structure.

The term "specific binding pair member" as used herein refers to a pair of molecules that are capable of specifically binding to each other, e.g., enzyme-substrate, antigen-antibody, ligand-receptor. An example of a specific binding pair member pair is the biotin-streptavidin system, where "biotin" is widely present in animal and plant tissues and has two cyclic structures on the molecule, an imidazolone ring and a thiophene ring, respectively, where the imidazolone ring is the main site for binding to streptavidin. Activated biotin can be conjugated to almost any biological macromolecule known, including proteins, nucleic acids, polysaccharides, lipids, and the like, mediated by a protein cross-linking agent; "streptavidin" is a protein secreted by Streptomyces and has a molecular weight of 65 kD. The "streptavidin" molecule consists of 4 identical peptide chains, each of which is capable of binding a biotin. Thus, each antigen or antibody can be conjugated to multiple biotin molecules simultaneously, thereby creating a "tentacle effect" that increases assay sensitivity. Any reagent used in the present invention, including antigens, antibodies, can be conjugated to any member of the biotin-streptavidin specific binding pair as desired.

The term "donor" as used herein refers to a sensitizer capable of generating a reactive intermediate such as singlet oxygen that reacts with an acceptor upon activation by energy or an active compound. The donor may be photoactivated (e.g., dyes and aromatic compounds) or chemically activated (e.g., enzymes, metal salts, etc.). In some embodiments of the invention, the donor is a photosensitizer which may be a photosensitizer known in the art, preferably a compound that is relatively light stable and does not react efficiently with singlet oxygen, non-limiting examples of which include compounds such as methylene blue, rose bengal, porphyrins, phthalocyanines, and chlorophylls disclosed in, for example, U.S. Pat. No. 5,5709994, which is incorporated herein by reference in its entirety, as well as derivatives of these compounds having 1 to 50 atom substituents that serve to render these compounds more lipophilic or more hydrophilic, and/or as a linker group to a member of a specific binding pair. Examples of other photosensitizers known to those skilled in the art may also be used in the present invention, such as those described in US patent No. US6406913, which is incorporated herein by reference. In other embodiments of the invention, the donor is a chemically activated other sensitizer, non-limiting examples of which are certain compounds that catalyze the conversion of hydrogen peroxide to singlet oxygen and water. Other examples of donors include: 1, 4-dicarboxyethyl-1, 4-naphthalene endoperoxide, 9, 10-diphenylanthracene-9, 10-endoperoxide, etc., which are heated or directly absorb light to release singlet oxygen.

the term "acceptor" as used herein refers to a compound capable of reacting with singlet oxygen to produce a detectable signal. The donor is induced by energy or an active compound to activate and release singlet oxygen in a high energy state that is trapped by a close proximity acceptor, thereby transferring energy to activate the acceptor. In some embodiments of the invention, the acceptor is a substance that undergoes a chemical reaction with singlet oxygen to form an unstable metastable intermediate that can decompose with or subsequently emit light. Typical examples of such substances include, but are not limited to: enol ether, enamine, 9-alkylidene xanthan gum, 9-alkylidene-N-alkyl acridin, aromatic vinyl ether, diepoxy ethylene, dimethyl thiophene, aromatic imidazole or lucigenin. In other embodiments of the invention, the acceptor is an alkene capable of reacting with singlet oxygen to form a hydroperoxide or dioxetane that can be decomposed into ketones or carboxylic acid derivatives; a stable dioxetane which can be decomposed by the action of light; acetylenes which can react with singlet oxygen to form diketones; hydrazones or hydrazides which can form azo compounds or azocarbonyl compounds, such as luminol; and aromatic compounds that can form endoperoxides. Specific, non-limiting examples of receptors that can be utilized in accordance with the disclosed and claimed invention are described in U.S. patent No. US5340716, which is incorporated herein by reference in its entirety. In other embodiments of the invention, the receptor comprises an olefinic compound and a metal chelate, which is non-particulated and soluble in an aqueous medium, as in the case of the receptor described in patent PCT/US2010/025433 (which is incorporated herein by reference in its entirety).

The 'donor' can be polymer particles filled with photosensitive compounds formed by coating functional groups on a substrate, and can generate singlet oxygen under the excitation of light; and/or the acceptor can be polymer particles filled with the luminescent compound and the lanthanide element formed by coating the functional groups on the substrate.

The "matrix" according to the present invention is microspheres or microparticles known to the skilled person, of any size, which may be organic or inorganic, which may be expandable or non-expandable, which may be porous or non-porous, which have any density, but preferably have a density close to that of water, preferably are capable of floating in water, and which are made of a transparent, partially transparent or opaque material. The substrate may or may not have a charge, and when charged, is preferably negatively charged. The matrix may be a solid (e.g., polymers, metals, glass, organic and inorganic substances such as minerals, salts and diatoms), oil droplets (e.g., hydrocarbons, fluorocarbons, siliceous fluids), vesicles (e.g., synthetic such as phospholipids, or natural such as cells, and organelles). The matrix may be latex particles or other particles containing organic or inorganic polymers, lipid bilayers such as liposomes, phospholipid vesicles, oil droplets, silica particles, metal sols, cells and microcrystalline dyes. The matrix is generally multifunctional or capable of binding to a donor or recipient by specific or non-specific covalent or non-covalent interactions. Many functional groups are available or incorporated. Typical functional groups include carboxylic acid, acetaldehyde, amino, cyano, vinyl, hydroxy, mercapto, and the like. One non-limiting example of a matrix suitable for use in the present invention is a carboxyl modified latex particle. Details of such substrates can be found in U.S. patent nos. US5709994 and US5780646 (both of which are incorporated herein by reference in their entirety).

The term "epitope" as used herein refers to any protein determinant capable of specifically binding to an immunoglobulin or T cell receptor. In some embodiments of the invention, an epitope is a region of the antigen surface that can be specifically assembled by an antibody. Epitope determinants may generally include chemically active surface groups of the molecule such as, but not limited to: amino acids, sugar side chains, phosphoryl groups and/or sulfonyl groups. In other embodiments of the invention, epitopes may be characterized by specific three-dimensional structural features as well as specific charge characteristics.

The term "heterogeneous chemiluminescent immunoassay kit" as used herein refers to all reagents or combinations of reagents necessary for a heterogeneous chemiluminescent immunoassay.

in the present invention, the phrase "detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel" refers to "biomarker combination test".

embodiments II

As mentioned above, some atypical early stage and/or seronegative patients are often misdiagnosed and missed because RA is heterogeneous in appearance. In order to improve the existing diagnostic strategy for RA and improve the diagnostic level, the present inventors have conducted extensive studies on the RA diagnostic method.

The research of the inventor finds that the 14-3-3eta protein is remarkably increased in RA serum and joint synovial fluid and can up-regulate the expression of a plurality of inflammatory factors related to RA, which indicates that the protein is possibly involved in RA disease occurrence. The inventor further finds that the levels of the serum 14-3-3eta protein, the anti-CCP antibody and the anti-Carp antibody are jointly detected and the detection result is correlated with RA by detecting the levels of the serum 14-3-3eta protein, the anti-CCP antibody and the anti-Carp antibody of RA, non-RA inflammatory joint disease patients and contemporary healthy examinees, so that the detection accuracy of RA positivity of the RA inflammatory joint disease patients can be remarkably improved. The present invention has been made based on the above findings.

Accordingly, a first aspect of the present invention relates to the use of the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers for the preparation of a reagent for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers in the biomarker group; and

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

The second aspect of the invention relates to a use of detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel in the preparation of a reagent for evaluating the severity of Rheumatoid Arthritis (RA) by biochemical marker, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

The third aspect of the present invention relates to the use of the concentration of each biomarker in a panel of biomarkers for Rheumatoid Arthritis (RA) for the preparation of a formulation for the classification of Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical markers in the extra-corporeal region, comprising:

a) Respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In some embodiments of the invention, the other autoimmune diseases include other joint diseases; the other joint disease is Osteoarthritis (OA).

the fourth aspect of the present invention relates to the use of a Rheumatoid Arthritis (RA) biomarker panel for the preparation of a reagent for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a sample to be tested, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel as compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population using a heterogeneous chemiluminescent immunoassay method is indicative of the presence of RA;

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In the present invention, the sample to be tested is selected from blood, blood derivatives, serum, plasma, urine, cerebrospinal fluid, semen, saliva, synovial fluid, emphysema effusion and tissue, preferably the sample to be tested is selected from blood, plasma, serum, synovial fluid and tissue, more preferably the sample to be tested is selected from blood, plasma and serum, and still more preferably the sample to be tested is serum.

in the present invention, Anti-CCP antibody is captured by one or more CCPs as antigens.

in the present invention, the Anti-carp antibody is captured by one or more carps as antigens.

In the present invention, the 14-3-3eta protein is captured by one or more antibodies to the 14-3-3eta protein.

in some preferred embodiments of the invention, the biomarker panel comprises Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies and other biomarkers, preferably the other biomarker is RA.

in some preferred embodiments of the invention, the concentration of each biomarker in the biomarker panel is detected using a heterogeneous chemiluminescence immunoassay.

according to some embodiments of the invention, the step of detecting the concentration of Anti-CCP antibodies using a heterogeneous chemiluminescence immunoassay comprises measuring the amount of immunocomplexes formed between Anti-CCP antibodies and at least one antigen using a heterogeneous chemiluminescence immunoassay.

in some embodiments of the invention, the amount of Anti-CCP antibody in the sample to be tested is determined based on an Anti-CCP standard working curve.

according to some embodiments of the invention, said step further comprises comparing the amount of immunocomplexes formed between said Anti-CCP antibody and at least one antigen measured with the amount of immunocomplexes formed between said Anti-CCP antibody and at least one antigen in a normal control sample, a rheumatoid arthritis control sample or a pre-treatment sample from the same subject.

According to some embodiments of the invention, the step comprises contacting the sample with a sample comprising a first antigen capable of specifically binding to the epitope binding site of Anti-CCP antibodies to form an immune complex, and further with an Anti-immune complex antibody capable of specifically recognizing and binding to Anti-CCP antibodies in the first immune complex formed with the first antigen, and not recognizing free, antigen-unbound Anti-CCP antibodies.

In some embodiments of the invention, the first antigen is a citrullinated antigen.

in some preferred embodiments of the invention, the first antigen is selected from the group consisting of synthetic citrullinated cyclic peptides, citrullinated linear peptides, polypeptides formed by synthesizing at least 2 single citrullinated peptide fragments on one peptide chain, a mixture of citrullinated peptide fragments comprising at least 2 single citrullinated peptide fragments, and citrullinated proteins

in some embodiments of the invention, the amount of 14-3-3eta protein in the test sample is determined based on a 14-3-3eta protein standard working curve.

in some embodiments of the invention, the antibody comprises a first antibody capable of specifically binding to a first epitope of 14-3-3eta protein and a second antibody capable of specifically binding to a second epitope of 14-3-3eta protein, wherein the second epitope and the first epitope do not overlap.

In the present invention, the first antibody binds to a receptor capable of reacting with singlet oxygen to generate a detectable chemiluminescent signal.

In some embodiments of the invention, the acceptor comprises an olefinic compound and a metal chelate, which is in non-particulate form and soluble in an aqueous medium; and/or the acceptor is polymer particles filled with a luminescent compound and lanthanide.

In the present invention, the first antibody and the second antibody are each independently selected from a monoclonal antibody and/or a polyclonal antibody, preferably a monoclonal antibody.

In some embodiments of the invention, the amino acid SEQUENCE of the 14-3-3eta protein or fragment thereof is as shown in SEQUENCE No. 1.

in some further embodiments of the invention, the epitope is selected from the group consisting of relatively specific fragments whose amino acid fragments are sequences of 14-3-3eta protein: 1-6aa, 27-38aa, 71-83aa, 112-154 aa and 141-154 aa.

The fifth to twenty-first aspects below further provide specific embodiments for implementing the invention.

The fifth aspect of the present invention relates to a kit for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in the Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises an Anti-CCP antibody, a 14-3-3eta protein and an Anti-carp antibody.

the sixth aspect of the present invention relates to a kit for assessing the severity of Rheumatoid Arthritis (RA) in vitro by biochemical markers based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in the Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein, and Anti-carp antibody.

the seventh aspect of the present invention relates to a kit of reagents for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemical marker extracorporeally based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising reagents for detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein, and Anti-carp antibody.

an eighth aspect of the invention relates to a kit of reagents for the in vitro assessment of the presence or absence of Rheumatoid Arthritis (RA) in a sample to be tested using a Rheumatoid Arthritis (RA) biomarker panel, wherein an increase in the combined concentration value measured for each biomarker in the Rheumatoid Arthritis (RA) biomarker panel as compared to the truncated combined concentration value for each marker in the corresponding biomarker panel measured from a reference population using a heterogeneous chemiluminescent immunoassay method is indicative of the presence of RA; wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

In the present invention, Anti-CCP antibody is captured by one or more CCPs as antigens.

In the present invention, the Anti-carp antibody is captured by one or more carps as antigens.

In the present invention, the 14-3-3eta protein is captured by one or more antibodies to the 14-3-3eta protein.

In some preferred embodiments of the invention, the biomarker panel comprises Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies and other biomarkers, preferably the other biomarker is RA.

A ninth aspect of the invention relates to a kit for assessing the presence or absence of Rheumatoid Arthritis (RA) by biochemical marker ex vivo based on the concentration of each biomarker in a set of Rheumatoid Arthritis (RA) biomarkers, comprising a kit of reagents according to the fifth to eighth aspects of the invention.

A tenth aspect of the invention relates to a kit for assessing the severity of Rheumatoid Arthritis (RA) by means of biochemical markers in addition to the biomarkers based on the concentration of each biomarker in a set of Rheumatoid Arthritis (RA) biomarkers, comprising a kit of reagents according to the fifth to eighth aspects of the invention.

An eleventh aspect of the invention relates to a kit for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemically labeling extra-corporeal regions based on the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel, comprising the kit of reagents according to the fifth to eighth aspects of the invention.

A twelfth aspect of the invention relates to a kit for assessing the presence of Rheumatoid Arthritis (RA) in a test sample in vitro using a Rheumatoid Arthritis (RA) biomarker panel, comprising a kit according to the fifth to eighth aspects of the invention.

a thirteenth aspect of the present invention relates to a method for assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using a kit of reagents according to the fifth to eighth aspects of the present invention or using a kit according to the ninth to twelfth aspects of the present invention and assessing the presence or absence of Rheumatoid Arthritis (RA) in vitro by biochemical markers.

In some embodiments of the invention, the method comprises:

a) respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers in the biomarker group; and

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in some further embodiments of the invention, the combined concentration values of step b) are compared to cut-off values derived from a reference population other than RA positive patients, said reference population comprising apparently healthy persons and patients selected from Osteoarthritis (OA) patients and other autoimmune disease patients.

A fourteenth aspect of the present invention relates to a method for assessing the severity of Rheumatoid Arthritis (RA) by the presence of biochemical markers, comprising detecting the concentration of each biomarker in a panel of Rheumatoid Arthritis (RA) biomarkers using a kit of reagents according to the fifth to eighth aspects of the present invention or using a kit according to the ninth to twelfth aspects of the present invention and assessing the severity of Rheumatoid Arthritis (RA) by the presence of biochemical markers.

In some embodiments of the invention, the method comprises:

a) respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

The fifteenth aspect of the present invention relates to a method for classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemically labeling extra-corporeal regions, which comprises detecting the concentration of each biomarker in a Rheumatoid Arthritis (RA) biomarker panel using a reagent set according to the fifth to eighth aspects of the present invention or using a kit according to the ninth to twelfth aspects of the present invention and classifying Rheumatoid Arthritis (RA) from other autoimmune diseases by biochemically labeling extra-corporeal regions.

In some embodiments of the invention, the method comprises:

a) respectively detecting the concentration of each biomarker in the biomarker group in a sample to be detected;

b) Combining a) the measured concentration values of the biomarkers to obtain a combined concentration value of the biomarkers; and

Wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in some further embodiments of the invention, the other autoimmune diseases include other joint diseases; the other joint disease is Osteoarthritis (OA).

a sixteenth aspect of the invention relates to a method for assessing in vitro the presence or absence of Rheumatoid Arthritis (RA) in a test sample using a kit of reagents according to the fifth to eighth aspects of the invention or using a kit according to the ninth to twelfth aspects of the invention, wherein an increase in the combined concentration value measured for each biomarker in the set of Rheumatoid Arthritis (RA) biomarkers compared to the truncated combined concentration value for each marker in the corresponding set of biomarkers measured from a reference population is indicative for the presence of RA;

wherein the biomarker panel comprises Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody.

in some preferred embodiments of the invention, the set of biomarkers comprises Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies and other biomarkers.

In some particularly preferred embodiments of the invention, the other biomarker is RA.

According to some preferred embodiments of the present invention, the kit comprises reagents for detecting the concentration of Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody in the biomarker panel by heterogeneous chemiluminescence immunoassay.

In some particularly preferred embodiments of the present invention, the heterogeneous chemiluminescent immunoassay reagent for the detection of Anti-CCP antibodies comprises:

component a1 comprising a solid support and, directly or indirectly bound thereto, a first antigen capable of specifically binding to an epitope binding site of an anti-CCP antibody;

In some embodiments of the present invention, the reagent further comprises Anti-CCP pure product as a calibrator, and the calibrator is diluted by calibrator diluent to working calibrator solutions with different concentrations according to a proportional gradient.

In some preferred embodiments of the invention, the first antigen is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antigen is bound to biotin and the solid support is bound to streptavidin.

In other preferred embodiments of the invention, the anti-immune complex antibody binds to one member of a specific binding pair member and the label binds to the other member of the specific binding pair member; preferably, the anti-immune complex antibody binds to biotin and the label binds to streptavidin.

In some preferred embodiments of the present invention, component c1, a substrate solution, said substrate solution comprising a1 solution and a B1 solution, preferably said a1 solution is a hydrogen peroxide solution, preferably said B1 solution is a sodium hydroxide solution.

In the present invention, the anti-immunocomplex antibody binds to the anti-CCP antibody in the first immunocomplex through a recognition epitope, which is a conformational epitope and/or a linear epitope.

In some embodiments of the invention, the anti-immune complex antibodies recognize a constant region portion of an anti-CCP antibody in a first immune complex.

in some embodiments of the invention, the anti-immune complex antibodies do not recognize the light chain portion of the anti-CCP antibodies in the first immune complex.

in other embodiments of the invention, the anti-immune complex antibodies specifically recognize the Fc fragment of the anti-CCP antibody in the first immune complex.

in some embodiments of the invention, the anti-immune complex antibody is a polyclonal antibody and/or a monoclonal antibody.

In some preferred embodiments of the invention, the anti-immune complex antibody is a monoclonal antibody.

In the present invention, the method for preparing the polyclonal antibody comprises: immunizing an animal by using a human immune complex to obtain animal serum containing the polyclonal antibody; and purifying the animal serum by affinity chromatography to obtain the polyclonal antibody for specifically recognizing the human immune complex.

In the present invention, the method for preparing the monoclonal antibody comprises: fusing spleen cells of mice immunized by the human immune complex with mouse myeloma cells, culturing, detecting cell culture supernatant, and reserving positive cell strains.

according to the invention, the first antigen is a citrullinated antigen.

In some embodiments of the invention, the first antigen is selected from the group consisting of synthetic citrullinated cyclic peptides, citrullinated linear peptides, polypeptides formed by synthesizing at least 2 single citrullinated peptide fragments on one peptide chain, a mixture of citrullinated peptide fragments comprising at least 2 single citrullinated peptide fragments, and citrullinated proteins.

In some preferred embodiments of the invention, the first antigen is selected from the group consisting of a synthetic cyclic citrulline-containing cyclic peptide, a citrulline-containing linear peptide, a polypeptide formed by synthesizing at least 2 single citrulline-containing peptide fragments on one peptide chain, and a citrulline peptide fragment mixture comprising at least 2 single citrulline-containing peptide fragments; preferably, the first antigen is a polypeptide synthesized on one peptide chain by 2-4 citrulline-containing peptide fragments or a citrulline peptide fragment mixture containing 2-4 single citrulline-containing peptide fragments.

In some preferred embodiments of the present invention, the citrullinated peptide fragment is selected from SEQ ID nos. 2-5.

TABLE 1

Serial number	Sequence of
		SEQ ID No.2	ring- (HQCHQEST-Cit-GRSRGRCGRSGS)
SEQ ID No.3	ARGGSRERARGRGRG-Cit-GEKR
		SEQ ID No.4	GGSKTSLYNLR-Cit-GTALAIPQ
SEQ ID No.5	APPPISGGGY-cit-A-cit-PAKAAAT

in some preferred embodiments, the first antigen is indirectly linked to a solid support.

In some embodiments of the invention, the concentration of the solid support and the first antigen bound thereto in component a1 is 1-100mg/mL, preferably 10-50 mg/mL.

In some embodiments of the invention the concentration of the first label and the second antibody or binding fragment thereof bound thereto in component b1 is 1-100mg/mL, preferably 10-50 mg/mL.

in some further particularly preferred embodiments of the invention, the concentration of Anti-CCP antibody is detected by a heterogeneous chemiluminescent immunoassay using a heterogeneous chemiluminescent immunoassay kit comprising Anti-CCP antibody, 14-3-3eta protein and Anti-carp antibody, comprising:

Step R1, mixing a sample to be tested with the component a1 to obtain a first mixture;

Step R2, mixing the first mixture with component b1 to obtain a second mixture;

Step R3, mixing the second mixture with component c1 to obtain a third mixture which generates a detectable chemiluminescent signal;

and step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of Anti-CCP antibody.

In some preferred embodiments of the present invention, the method further comprises the step of preparing an Anti-CCP standard working curve before step R1.

In some further preferred embodiments of the present invention, in step R4, the intensity of the chemiluminescent signal in step R3 is detected, and the content of Anti-CCP antibody in the sample to be tested is determined based on the Anti-CCP standard working curve.

in some particularly preferred embodiments of the invention, the heterogeneous chemiluminescent immunoassay reagent for the detection of 14-3-3eta protein comprises:

Component b2 comprising a first label capable of reacting with a substrate or capable of catalysing the substrate to generate a detectable signal and a second antibody or binding fragment thereof directly or indirectly bound to said first label, said second antibody or binding fragment thereof being capable of specifically binding to a second epitope of 14-3-3eta protein, said second epitope and said first epitope not overlapping.

in the invention, the amino acid SEQUENCE of the 14-3-3eta protein is shown as SEQUENCE NO. 1. Preferably, the second epitope and the first epitope are each independently selected from relatively specific fragments of the sequence of amino acid fragment 14-3-3eta protein: 1-6aa, 27-38aa, 71-83aa, 112-154 aa and 141-154 aa.

in the present invention, the first antibody and the second antibody are each independently selected from a monoclonal antibody and/or a polyclonal antibody, preferably a monoclonal antibody.

In some preferred embodiments of the present invention, the reagent further comprises 14-3-3eta protein as a calibrator diluted by a calibrator diluent in a proportional gradient to working calibrator solutions of different concentrations.

in some preferred embodiments of the invention, the first antibody or binding fragment thereof is bound to one member of a specific binding pair member and the solid support is bound to the other member of the specific binding pair member; preferably, the first antibody or binding fragment thereof is bound to biotin and the solid support is bound to streptavidin.

in further preferred embodiments of the invention, the second antibody or binding fragment thereof is bound to one member of a specific binding pair member and the first label is bound to the other member of the specific binding pair member; preferably, the second antibody or binding fragment thereof is bound to biotin and the first label is bound to streptavidin.

In some embodiments of the present invention, the concentration of the solid phase carrier and the first antibody or binding fragment thereof bound thereto in component a2 is 1-100mg/mL, preferably 10-50 mg/mL; and/or the concentration of the first label and the second antibody or binding fragment thereof bound thereto in component b2 is 1-100mg/mL, preferably 10-50 mg/mL.

In the invention, the first marker is a chemiluminescent marker selected from luminol and derivatives thereof, isoluminol and derivatives thereof, acridinium ester and derivatives thereof, adamantane, rare earth elements and bipyridine ruthenium complex.

In the invention, the first marker is a chemiluminescent catalyst and is selected from horseradish peroxidase and alkaline phosphatase.

In the present invention, the solid phase carrier is selected from a microplate, a magnetic bead, a plastic particle and a plastic microsphere, and preferably the solid phase carrier is a magnetic bead.

in some embodiments of the invention, the reagent further comprises component c2, a substrate solution. Preferably, the substrate solutions comprise a2 solution and B2 solution. Further preferably, the a2 solution is a hydrogen peroxide solution, and the B2 solution is a sodium hydroxide solution.

in some preferred embodiments of the invention, the reagent further comprises a component d2 comprising a second label capable of reacting with the substrate or capable of catalyzing the substrate to generate a detectable signal, and a third antibody or binding fragment thereof directly or indirectly bound thereto, the third antibody or binding fragment thereof being capable of specifically binding to a second epitope of the 14-3-3eta protein, and the second epitope and the first epitope do not overlap.

In the present invention, the third antibody directly or indirectly binding to the second label and the second antibody directly or indirectly binding to the first label are the same antibodies binding to the same epitope of 14-3-3eta protein.

in some preferred examples, the third antibody or binding fragment thereof binds to one member of the specific binding pair member and the second label binds to the other member of the specific binding pair member; preferably, the third antibody or binding fragment thereof binds to biotin and the second label binds to streptavidin.

In the invention, the second marker is a chemiluminescent marker selected from luminol and derivatives thereof, isoluminol and derivatives thereof, acridinium ester and derivatives thereof, adamantane, rare earth elements and bipyridine ruthenium complex.

in the invention, the second marker is a chemiluminescent catalyst and is selected from horseradish peroxidase and/or alkaline phosphatase.

In some embodiments of the invention the concentration of the second label and the third antibody or binding fragment thereof bound thereto in component d2 is between 1 and 100mg/mL, preferably between 10 and 50 mg/mL.

in some further particularly preferred embodiments of the invention, the concentration of 14-3-3eta protein is detected by a heterogeneous chemiluminescent immunoassay using a heterogeneous chemiluminescent immunoassay kit comprising Anti-CCP antibodies, 14-3-3eta protein and Anti-Carp antibodies, comprising:

step R1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step R2, mixing the third mixture with component c2 to obtain a fourth mixture which generates a detectable signal;

And step R3, detecting the existence and/or the intensity of the chemiluminescence signal in the step R2, thereby judging whether the 14-3-3eta protein exists in the sample to be detected and/or determining the content of the 14-3-3eta protein.

In some embodiments of the invention, the method further comprises the step of preparing a 14-3-3eta protein standard working curve before step R1.

In some further embodiments of the present invention, in step R3, the intensity of the chemiluminescent signal of step R2 is detected, and the content of 14-3-3eta protein in the sample to be tested is determined based on the standard working curve of 14-3-3eta protein.

in yet another further particularly preferred embodiment of the present invention, the concentration of 14-3-3eta protein is detected by a heterogeneous chemiluminescent immunoassay using a heterogeneous chemiluminescent immunoassay kit comprising Anti-CCP antibodies, 14-3-3eta protein and Anti-Carp antibodies, comprising:

Step T1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step T2, mixing the third mixture with component d2 to obtain a fifth mixture;

a step T3 of mixing the fifth mixture with component c2 to obtain a sixth mixture generating a detectable signal;

in some embodiments of the invention, the method further comprises the step of preparing a standard working curve for the 14-3-3eta protein prior to step T1.

In some further embodiments of the present invention, in step T4, the intensity of the chemiluminescent signal of step T3 is detected, and the content of 14-3-3eta protein in the sample to be tested is determined based on the standard working curve of 14-3-3eta protein.

In some particularly preferred embodiments of the invention, the heterogeneous chemiluminescent immunoassay reagent for the detection of Anti-Carp antibodies comprises:

Component a3 comprising a solid support and, directly or indirectly bound thereto, a first antigen capable of specifically binding to an epitope binding site of an anti-Carp antibody;

Component b3 comprising a label capable of reacting with a substrate or capable of catalyzing the substrate to generate a detectable signal and an anti-immune complex antibody directly or indirectly bound thereto, said anti-immune complex antibody being capable of specifically recognizing and binding to an anti-Carp antibody in a first immune complex formed with a first antigen, and not recognizing a free, unbound anti-Carp antibody.

In some preferred embodiments of the present invention, component c3, a substrate solution, said substrate solution comprising A3 solution and a B3 solution, preferably said A3 solution is a hydrogen peroxide solution, preferably said B3 solution is a sodium hydroxide solution.

In the present invention, the anti-immune complex antibody binds to the anti-Carp antibody in the first immune complex via a recognition epitope, which is a conformational epitope and/or a linear epitope.

In some embodiments of the invention, the anti-immune complex antibody recognizes a constant region portion of an anti-Carp antibody in a first immune complex.

In some embodiments of the invention, the anti-immune complex antibody does not recognize the light chain portion of the anti-Carp antibody in the first immune complex.

In other embodiments of the invention, the anti-immune complex antibody specifically recognizes the Fc fragment of the anti-Carp antibody in the first immune complex.

In some preferred embodiments of the invention, the amino acid sequence of the recognition epitope comprises 5 to 10 amino acids.

In some embodiments of the invention, the anti-immune complex antibody is a polyclonal antibody and/or a monoclonal antibody.

In some preferred embodiments of the invention, the anti-immune complex antibody is a monoclonal antibody.

according to the invention, the first antigen is a carbamoylated antigen.

in some embodiments of the invention, the first antigen is selected from the group consisting of a synthetic carbamylated peptide, a polypeptide formed on a peptide chain by synthesis of at least 2 single carbamylated peptide, a mixture of carbamylated peptide containing at least 2 single carbamylated peptide, and a carbamylated protein.

in some preferred embodiments of the invention, the first antigen is selected from the group consisting of a synthetic carbamylated peptide, a polypeptide formed on one peptide chain by synthesis of at least 2 single carbamylated peptide, and a carbamylated peptide mixture comprising at least 2 single carbamylated peptide; preferably, the first antigen is a polypeptide synthesized on one peptide chain by 2-4 carbamylated peptide fragments or a carbamylated peptide fragment mixture containing 2-4 single carbamylated peptide fragments.

In some preferred embodiments of the invention, the carbamoylated peptide fragment is selected from the group consisting of SEQ ID No.6 to SEQ ID No. 9.

TABLE 2

serial number	Sequence of
		SEQ ID No.6	HQCHQEST-Hcit-GKSKGKCGKSGS
SEQ ID No.7	CKAAATQ-Hcit-KVERCARRR
		SEQ ID No.8	NEAN-Hcit-YQISVN-Hcit-YRG
SEQ ID No.9	NEEGFFSA-Hcit-GHRPLDKK

In some embodiments of the invention, the molar ratio of the plurality of different peptide fragments in the first antigen to each other is the same for a polypeptide formed on one peptide chain synthesized from at least 2 single carbamylated peptide fragments.

In other embodiments of the invention, the mass ratio of the plurality of different peptidyl fragments in the first antigen to each other is the same for a carbamylated peptidyl fragment mixture containing at least 2 single carbamylated peptidyl fragments.

it will be appreciated by those skilled in the art that for reducing steric hindrance, a first antigen selected from the group consisting of a synthetic carbamylated peptide, a polypeptide synthesized on one peptide chain from at least 2 single carbamylated peptides, and a mixture of carbamylated peptides containing at least 2 single carbamylated peptides can be bound to the receptor via an intermediate which is a hydrophilic polymeric substance.

in some embodiments of the invention, the intermediate is a protein, preferably selected from the group consisting of hemocyanin, ovalbumin, bovine serum albumin, and bovine thyroglobulin.

in other embodiments of the present invention, the intermediate is selected from the group consisting of dendrimers, polycarboxylates, polymercaptans, and polyethylene glycols.

the mode of coupling the first antigen of the carbamylated peptide fragment mixture containing at least 2 single carbamylated peptide fragments to the intermediate is not particularly limited in the present invention, and the carbamylated peptide fragment mixture can be formed by coupling the intermediate separately from each single carbamylated peptide fragment and then mixing the coupled intermediate; or a formylated peptide fragment mixture formed by mixing single formylated peptide fragments and then coupling an intermediate to form a coupled intermediate; preferably, the individual formylated peptide fragments are mixed to form a mixture of formylated peptide fragments, which are then coupled to an intermediate to form a mixture of carbamylated peptide fragments coupled to an intermediate.

In some embodiments of the invention, the concentration of the receptor and anti-immune complex antibody bound thereto is 10-200. mu.g/mL, preferably 20-150. mu.g/mL, more preferably 25-100. mu.g/mL.

In other embodiments of the invention, the concentration of the first antigen and the member of the specific binding pair to which it binds is from 0.1 to 10. mu.g/mL, preferably from 0.5 to 5. mu.g/mL, more preferably from 1 to 3. mu.g/mL.

In some further particularly preferred embodiments of the invention, the concentration of Anti-Carp antibody is detected by a heterogeneous chemiluminescent immunoassay using a heterogeneous chemiluminescent immunoassay kit comprising the Anti-Carp antibody and the Anti-Carp antibody, comprising:

Step R1, mixing a sample to be tested with the component a3 to obtain a first mixture;

Step R2, mixing the first mixture with component b3 to obtain a second mixture;

Step R3, mixing the second mixture with component c3 to obtain a third mixture which generates a detectable chemiluminescent signal;

and step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of Anti-CCP antibody.

In some preferred embodiments of the invention, the method further comprises the step of preparing an Anti-Carp antibody standard working curve before step R1.

In some further preferred embodiments of the present invention, in step R4, the intensity of the chemiluminescent signal described in step R3 is detected, and the content of Anti-Carp antibody in the sample to be tested is determined based on the Anti-Carp antibody standard working curve.

An eighteenth aspect of the invention provides the chemiluminescent immunoassay analyzer of the use of the seventeenth aspect comprising:

A sample filling module for filling a sample to be tested of a subject suspected of having rheumatoid arthritis to a preset position of a chemiluminescence analyzer;

the reagent filling module is used for filling the pipettes of various reagents to the preset position of the chemiluminescence analyzer;

The incubation module is used for providing a proper incubation reaction environment for immunoreaction of a sample to be detected and a reagent;

A detection module for detecting the chemiluminescence signal and determining the concentration of the target molecule in the sample to be detected

in a nineteenth aspect of the present invention, there is provided a homogeneous immunoassay method for detecting Anti-CCP, using the chemiluminescent immunoassay system according to the eighteenth aspect of the present invention, and a heterogeneous immunoassay kit or kit containing a reagent for detecting Anti-CCP, 14-3-3eta protein and Anti-carp antibody according to the present invention, for detecting the concentration of Anti-CCP by homogeneous immunoassay, comprising:

Step R1, mixing a sample to be tested with the component a1 to obtain a first mixture;

step R2, mixing the first mixture with component b1 to obtain a second mixture;

step R3, mixing the second mixture with component c1 to obtain a third mixture which generates a detectable chemiluminescent signal;

And step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of Anti-CCP antibody.

In some embodiments of the invention, the method further comprises the step of preparing an Anti-CCP standard working curve before step R1.

step R1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

step R2, mixing the third mixture with component c2 to obtain a fourth mixture which generates a detectable signal;

Or comprises the following steps:

Step T1, mixing a sample to be tested with the component a2 and the combination b2 to obtain a third mixture;

Step T2, mixing the third mixture with component d2 to obtain a fifth mixture;

A step T3 of mixing the fifth mixture with component c2 to obtain a sixth mixture generating a detectable signal;

In some embodiments of the invention, the method further comprises the step of preparing a standard working curve for the 14-3-3eta protein prior to step R1 or T1.

according to a twenty-first aspect of the present invention, there is provided a homogeneous immunoassay method for detecting an Anti-Carp antibody using the chemiluminescent immunoassay system according to the eighteenth aspect of the present invention and a homogeneous immunoassay kit or kit comprising a homogeneous immunoassay reagent set for detecting Anti-CCP antibody, 14-3-3eta protein and Anti-Carp antibody according to the present invention for detecting the concentration of the Anti-Carp antibody by homogeneous immunoassay, comprising:

Step R1, mixing a sample to be tested with the component a3 to obtain a first mixture;

step R2, mixing the first mixture with component b3 to obtain a second mixture;

Step R3, mixing the second mixture with component c3 to obtain a third mixture which generates a detectable chemiluminescent signal;

And step R4, detecting the intensity of the chemiluminescence signal in the step R3, thereby determining the content of the Anti-Carp antibody.

In some embodiments of the invention, the method further comprises the step of creating an Anti-Carp antibody standard working curve prior to step R1.

It will be appreciated by those skilled in the art that the present invention may employ heterogeneous or heterogeneous and homogeneous chemiluminescent immunoassay reagents, kits or kits to detect Anti-CCP antibodies, 14-3-3eta protein and Anti-carp antibodies using heterogeneous or heterogeneous and homogeneous chemiluminescent immunoassay methods, and then statistically combining the three test results from the same sample to improve the accurate diagnosis of the same sample.

according to some embodiments of the invention, the kit of reagents according to the invention may further comprise other reagents.

in some particularly preferred embodiments of the invention, the homogeneous immunoassay reagent for detecting 14-3-3eta protein comprises:

Component a4 comprising a receptor capable of reacting with singlet oxygen to generate a detectable signal and a first antibody or binding fragment thereof bound thereto, said first antibody or binding fragment thereof being capable of specifically binding to a first epitope of a 14-3-3eta protein;

component b4 comprising a second antibody or binding fragment thereof capable of specifically binding to a second epitope of 14-3-3eta protein, said second epitope and said first epitope not overlapping;

Component c4 comprising a donor capable of generating singlet oxygen in an excited state.

In some embodiments of the invention, the amino acid SEQUENCE of the 14-3-3eta protein is shown as SEQUENCE No. 1. Preferably, the second epitope and the first epitope are each independently selected from relatively specific fragments of the sequence of amino acid fragment 14-3-3eta protein: 1-6aa, 27-38aa, 71-83aa, 112-154 aa and 141-154 aa.

In the present invention, the first antibody and the second antibody are each independently selected from a monoclonal antibody and/or a polyclonal antibody, preferably a monoclonal antibody.

In some preferred embodiments of the invention, the second antibody or binding fragment thereof binds to one member of the specific binding pair member and the donor binds to the other member of the specific binding pair member. Preferably, the second antibody or binding fragment thereof binds to biotin and the donor binds to streptavidin.

In some embodiments of the invention, the concentration of the receptor and the first antibody or binding fragment thereof bound thereto in component a4 is 10-200 μ g/mL, preferably 20-150 μ g/mL, more preferably 30-100 μ g/mL, most preferably 40-80 μ g/mL; and/or the concentration of the second antibody or binding fragment thereof in component b4 is 0.1-8 μ g/mL, preferably 0.2-6 μ g/mL, more preferably 0.4-4 μ g/mL, most preferably 0.6-2 μ g/mL; and/or the concentration of the donor in component c4 is 5-20. mu.g/mL, preferably 8-15. mu.g/mL, more preferably 10-12. mu.g/mL.

In the present invention, the acceptor comprises an olefin compound and a metal chelate compound, which are in a non-particulate form and are soluble in an aqueous medium; and/or the acceptor is polymer particles filled with a luminescent compound and lanthanide.

In the present invention, the donor is a photoactivated or chemically activated sensitizer, which is in a non-particulate form and soluble in an aqueous medium; and/or the donor is polymer particles filled with photosensitive compounds and can generate singlet oxygen under the excitation of light.

In some further particularly preferred embodiments of the invention, the concentration of 14-3-3eta protein is measured by a homogeneous immunoassay using a homogeneous immunoassay kit comprising Anti-CCP antibodies and 14-3-3eta protein, comprising:

Step R1, mixing a sample to be tested with the component a4 and the combination b4 to obtain a third mixture;

step R2, mixing the third mixture with component c4 to obtain a fourth mixture;

Step R3 of contacting an energy or reactive compound with said fourth mixture to excite said donor to produce singlet oxygen and said acceptor being capable of reacting with the singlet oxygen received to generate a detectable chemiluminescent signal;

And step R4, detecting the existence and/or the intensity of the chemiluminescence signal in the step R3, thereby judging whether the 14-3-3eta protein exists in the sample to be detected and/or determining the content of the 14-3-3eta protein.

In some embodiments of the invention, the method further comprises the step of preparing a 14-3-3eta protein standard working curve before step R1.

in some further embodiments of the present invention, in step R4, the intensity of the chemiluminescent signal of step R3 is detected, and the content of 14-3-3eta protein in the sample to be tested is determined based on the standard working curve of 14-3-3eta protein.

In the present invention, there is no separation and/or washing step between steps R1 and R2 and between steps R2 and R3.

In some embodiments, in step R3, the fourth mixture is irradiated with excitation light with a wavelength of 600-700nm to excite the donor to generate singlet oxygen, and the acceptor reacts with the contacted singlet oxygen to generate emission light with a wavelength of 520-620 nm.

According to some preferred embodiments, the kit of reagents according to the invention comprises homogeneous immunodetection reagents for the detection of Anti-carp antibodies, comprising:

Component a5 comprising a receptor capable of reacting with singlet oxygen to generate a detectable signal and a first antigen bound thereto, the epitope of the first antigen being capable of specifically binding to a first binding site of an epitope of an anti-Carp antibody;

Component b5 comprising a second antigen capable of specifically binding to a second epitope binding site of an anti-Carp antibody, the first epitope binding site and the second epitope binding site of the anti-Carp antibody not overlapping;

Component c5 comprising a donor capable of generating singlet oxygen in an excited state.

In the present invention, the first antigen and the second antigen are carbamoylated antigens; preferably, the carbamylated antigen is carbamylated human serum albumin; further preferably, the human serum albumin is shown in SEQ ID No. 6.

in some embodiments of the invention, the reagent further comprises an anti-Carp antibody pure product as a calibrator diluted by a calibrator diluent in a proportional gradient to working calibrator solutions of different concentrations.

in some preferred embodiments of the invention, the second antigen is bound to one member of a specific binding pair and the donor is bound to the other member of the specific binding pair. Preferably, the second antigen is bound to biotin and the donor is bound to streptavidin.

In some embodiments of the invention: the total concentration of the receptor and the first antigen bound thereto is 10-200. mu.g/mL, preferably 20-150. mu.g/mL, more preferably 25-100. mu.g/mL; and/or the total concentration of the second antigen and the member of the specific binding pair bound thereto is from 0.1 to 10. mu.g/mL, preferably from 0.5 to 5. mu.g/mL, more preferably from 1 to 3. mu.g/mL.

in the present invention, the acceptor comprises an olefin compound and a metal chelate compound, which are in a non-particulate form and are soluble in an aqueous medium; and/or the acceptor is polymer particles filled with a luminescent compound and lanthanide.

in the present invention, the donor is a photoactivated or chemically activated sensitizer, which is in a non-particulate form and soluble in an aqueous medium; and/or the donor is polymer particles filled with photosensitive compounds and can generate singlet oxygen under the excitation of light.

In some further preferred embodiments of the invention, the concentration of Anti-Carp is detected by homogeneous immunoassay using a homogeneous immunoassay kit containing Anti-Carp antibodies, which comprises the following steps:

Step R1, mixing a sample to be tested with the component a5 and the combination b5 to obtain a third mixture;

Step R2, mixing the third mixture with component c5 to obtain a fourth mixture;

And step R4, detecting the existence and/or the intensity of the chemiluminescence signal in the step R3, thereby judging whether the anti-Carp antibody exists in the sample to be detected and/or determining the content of the anti-Carp antibody.

In some embodiments of the invention, the method further comprises the step of preparing an anti-Carp antibody standard working curve prior to step R1.

in some further embodiments of the present invention, in step R4, the intensity of the chemiluminescent signal of step R3 is detected, and the amount of anti-Carp antibody in the test sample is determined based on an anti-Carp antibody standard working curve.

in the present invention, there is no separation and/or washing step between steps R1 and R2 and between steps R2 and R3.

in some embodiments of the present invention, in step R3, the fourth mixture is irradiated with excitation light with a wavelength of 600-700nm to excite the donor to generate singlet oxygen, and the acceptor reacts with the contacted singlet oxygen to generate emission light with a wavelength of 520-620 nm.

According to some preferred embodiments, the kit of reagents according to the invention comprises an electrochemiluminescence immunoassay reagent for detecting Anti-CCP antibodies, comprising:

component a6, comprising a solid support and a first antigen directly or indirectly bound thereto, wherein said first antigen is capable of specifically binding to a first recognition site of an epitope of an anti-cyclic citrullinated peptide antibody;

Component b6, comprising a label capable of undergoing an electrochemical reaction with a substrate under the action of a direct current electric field to generate a detectable signal, and a second antigen directly or indirectly bound thereto, the second antigen being capable of specifically binding to a second recognition site of an epitope of an anti-cyclic citrullinated peptide antibody;

component c6 comprising a substrate capable of undergoing an electrochemical reaction with a label under the influence of a direct current electric field to generate a detectable signal.

in the invention, the marker is terpyridyl ruthenium.

In the present invention, the substrate is tripropylamine.

In some embodiments of the invention, the reagent further comprises an anti-cyclic citrullinated peptide antibody pure product as a calibrator diluted by a calibrator diluent in a proportional gradient to working calibrator solutions of different concentrations.

in some embodiments of the invention, the first antigen and the second antigen are the same or different and are independently selected from the group consisting of synthetic citrullinated cyclic peptides, citrullinated linear peptides, polypeptides formed by synthesizing at least 2 single citrullinated peptide fragments on one peptide chain, a mixture of citrullinated peptide fragments comprising at least 2 single citrullinated peptide fragments, and citrullinated proteins.

In some specific embodiments of the present invention, the first antigen and the second antigen are each independently selected from the group consisting of a synthetic cyclic citrullinated cyclic peptide, a citrullinated linear peptide, a polypeptide formed by synthesizing at least 2 single citrullinated peptide fragments on one peptide chain, and a citrullinated peptide fragment mixture comprising at least 2 single citrullinated peptide fragments.

In some specific embodiments of the present invention, the first antigen and the second antigen are each independently a polypeptide synthesized on one peptide chain from 2 to 4 citrulline-containing peptide fragments or a citrulline peptide fragment mixture containing 2 to 4 single citrulline-containing peptide fragments; preferably, the peptide segment containing citrulline is selected from SEQ ID Nos. 2-5.

in some embodiments of the present invention, the method for detecting the concentration of Anti-CCP by electrochemical immunoassay using an electrochemical immunoassay kit containing Anti-CCP antibodies, corresponding to the above-mentioned reagents in the kit of the present invention, comprises the steps of:

Step R1, mixing a sample to be tested with the component a6 and the combination b6 to obtain a first mixture;

Step R2, mixing the first mixture with component c6 to obtain a second mixture;

Step R3, starting a direct current electric field on the second mixture, and enabling the second mixture to react to produce a detectable chemiluminescent signal;

And step R4, detecting the intensity of the chemiluminescence signal in the step R3, so as to judge the concentration of Anti-CCP antibody in the sample to be detected.

In some embodiments of the invention, the method further comprises the step of preparing an Anti-CCP standard working curve before step R1.

example III

In order that the present invention may be more readily understood, the following detailed description will proceed with reference being made to examples, which are intended to be illustrative only and are not intended to limit the scope of the invention. The starting materials or components used in the present invention may be commercially or conventionally prepared unless otherwise specified.

in the method of the present invention, all reagents may be mixed or mixed, and then mixed and/or incubated according to actual needs. Specifically, the temperature of the incubation can be any temperature in the temperature range of 25-45 ℃, and the incubation time can be overnight or 10-20 min.

52页详细技术资料下载

上一篇：一种医用注射器针头装配设备

下一篇：通过生物标记物联检体外评估类风湿性关节炎是否存在的方法

method for assessing whether rheumatoid arthritis exists in vitro through biomarker-associated sample

相关技术

网友询问留言